Considerations and Challenges in the Remdesivir COVID‐19 Pediatric Development Program
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Pharmacology"
DOI: 10.1002/jcph.2158
Abstract: The US Food and Drug Administration is committed to the development of effective antiviral regimens for pediatric patients with coronavirus disease 2019 (COVID‐19), including infants and neonates. On April 25, 2022, the approved indication of… read more here.
Keywords: covid pediatric; challenges remdesivir; considerations challenges; pediatric development ... See more keywords